The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.

Articles

FDA announced it had issued an emergency use authorization for convalescent plasma that would make it easier to provide this treatment to COVID-19 patients. 

FDA Caught in Political Crossfire

CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2. 

Oragenics and Avid Bioservices Collaborate on Coronavirus Vaccine

UK government has set up a new organization to replace Public Health England.

UK Gov Sets Up New Public Health Organization

EC finalizes agreement to purchase millions of doses of AstraZeneca's COVID-19 vaccine.

EC Reaches Agreement with AstraZeneca on Purchase of COVID-19 Vaccine

Novavax has signed an agreement with the UK government for 60 million doses of a COVID-19 vaccine and a Phase III clinical trial. 

Novavax Signs Term Sheet with UK Gov for COVID-19 Vaccine Doses

The collaboration will increase the supply of the potential treatment to at least three and a half times the current capacity.

Roche to Partner with Regeneron to Increase Supply of COVID-19 Treatment

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

A new FDA guidance provides answers to questions about when the agency will seek to visit a site during the COVID-19 pandemic and how it will respond when a needed inspection cannot be conducted safely. 

FDA May Delay Approval of Drugs Where Necessary Inspection Is Not Feasible

Hallie Forcinio is BioPharm International's packaging editor, editorhal@sbcglobal.net

Plastic primary packaging could help prevent supply chain shortages associated with high demand for COVID-19 vaccines.

Expanding Options for Vaccine Packaging 

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

FDA relies on risk assessments, border inspections, and compliance histories in place of routine audits during the COVID-19 pandemic.

FDA Takes Calculated Approach to Auditing during COVID-19

SK bioscience will manufacture the vaccine antigen component for use in the final drug product at its vaccine facility in Andong L-house, South Korea.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success